Viemed Healthcare CMO William Frazier Buys 10,000 Shares
William Frazier, Viemed's Chief Medical Officer, purchased 10,000 shares for $18,100.
Key Points
- William Frazier, Chief Medical Officer at Viemed Healthcare, bought 10,000 shares at $1.81 each, totaling $18,100 on June 25, 2026.
- Viemed Healthcare trades on NasdaqCM with a market cap of $445.9 million and a P/E ratio of 31.43.
- Institutional investors like Vanguard and Ameriprise increased their stakes in Viemed, while BlackRock and Goldman Sachs reduced theirs.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
William Frazier, the Chief Medical Officer of Viemed Healthcare, Inc. (NasdaqCM: VMD), made a significant purchase of company shares. On June 25, 2026, Frazier bought 10,000 shares at an average price of $1.81 each, amounting to a total investment of $18,100. This transaction was not part of a pre-planned trading program.
Insider Buying and Selling at Viemed Healthcare, Inc.
On June 25, 2026, William Frazier, Viemed's Chief Medical Officer, purchased 10,000 shares at $1.81 per share, totaling $18,100. This purchase was not under a Rule 10b5-1 plan. On the same day, Frazier also sold 10,000 shares at $11.72 each. Timothy Smokoff sold 20,000 shares at $11.50 on June 24, 2026, while Michael Moore, the President, sold shares in March 2026.
Other Institutional Activity in Viemed Healthcare
Institutional investors have shown varied interest in Viemed Healthcare. Vanguard Capital Management opened a new position with 1,303,384 shares valued at about $12 million. Ameriprise Financial increased its holdings by 75,506 shares, ending with 898,319 shares worth approximately $8.27 million, marking a 9.2% increase. Forager Capital Management also raised its stake by 40,000 shares, reaching a total of 2,825,871 shares valued at $26 million, a 1.4% increase. However, BlackRock trimmed its position slightly by 3,514 shares, maintaining 4,622,562 shares worth around $42.57 million. Goldman Sachs reduced its stake by 25,399 shares, holding 1,421,634 shares valued at $13.09 million, reflecting a 1.8% decrease.
Viemed Healthcare, Inc. Stock Up 31.9%
Shares of Viemed Healthcare (NasdaqCM: VMD) traded near $11.63 on Saturday. The company has a market capitalization of approximately $445.9 million and a P/E ratio of 31.43. Viemed's stock has experienced a 52-week low of $5.93 and a high of $11.88. The 50-day moving average is $9.89, while the 200-day moving average stands at $8.19. The company maintains a current ratio of 1.224 and a quick ratio of 1.006, with a debt-to-equity ratio of 8.53.
$VMD stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Viemed Healthcare reported revenue of $286.6 million, showing a growth of 27.5%. The company's net margin stands at 5.2%, with a return on equity of 10.89%. Earnings per share (EPS) is $0.37. The next earnings report is expected on August 5, 2026.
Analysts Set New Price Targets
Lake Street reiterated its buy rating for Viemed Healthcare with a price target of $15.00 on May 7, 2024. The consensus among analysts indicates an average target price of $11.00, with only one analyst providing an opinion.
About Viemed Healthcare
Viemed Healthcare, Inc., headquartered in Lafayette, Louisiana, operates in the healthcare sector, focusing on medical devices. The company provides home medical equipment and post-acute respiratory healthcare services across the United States. Viemed specializes in managing respiratory diseases, such as COPD, offering both invasive and non-invasive ventilation solutions. Founded in 2006, the company is led by CEO Casey Hoyt and employs approximately 1,387 people.
Bottom Line
William Frazier's recent purchase of Viemed Healthcare shares highlights insider confidence in the company's prospects. Investors keep a close watch on such insider activities as they can signal potential future developments. However, it's important to remember that insider transactions do not always indicate future performance. Viemed's recent earnings growth and analyst ratings suggest continued interest in the company's stock.
Get Viemed Healthcare, Inc. alerts
New 13F filings, insider trades, and analyst moves on $VMD, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.